



Syntheses and Hydrolysis of Basic and Dibasic Ampicillin Esters Tailored for Intracellular Accumulation

Isabelle Paternotte,^{a,b} Hua Juan Fan,^a Pascal Scrève,^a Michel Claesen,^a
Paul M. Tulkens^b and Etienne Sonveaux^{a,*}

^aUnité de Chimie Pharmaceutique et de Radiopharmacie, Université Catholique de Louvain,
Avenue E. Mounier 73 p.b. 7340, B-1200 Bruxelles, Belgium

^bUnité de Pharmacologie Cellulaire et Moléculaire, Université Catholique de Louvain,
Avenue E. Mounier 73 p.b. 7340, B-1200 Bruxelles, Belgium

Received 29 May 2000; accepted 4 October 2000

Abstract—Readily hydrolysable basic and dibasic esters of ampicillin were synthesised by alkylation of the carboxylate function of ampicillin to obtain prodrugs that may accumulate in cells and allow for an intracellular delivery of ampicillin (Fan et al., *Bioorg. Med. Chem. Lett.* **1997**, 7, 3107). We found that the β -lactam ring cleavage and the hydrolysis of the ester function were competitive reactions. The prerequisite for biological activity of compounds of this type is therefore that ester hydrolysis proceeds faster than ring opening. Some synthesised compounds show promise as prodrugs since they displayed a reasonable stability and regenerate large quantities of bioactive ampicillin in broth. © 2001 Elsevier Science Ltd. All rights reserved.

Introduction

We described in a previous short communication¹ the discovery of the cellular accumulation and intracellular antibacterial activity of basic ester prodrugs of ampicillin. These were original observations for β -lactams since, contrary to macrolides, fluoroquinolones and ansamycins, these antibiotics do not accumulate into cells and are therefore largely inefficient against most forms of intracellular infection.^{2,3} We observed that important points to get intracellular accumulation of β -lactams were (i) the esterification of the carboxylate function and (ii) the presence of a protonable amino group in the antibiotic. We describe here the synthetic procedures giving access to monobasic prodrug esters of ampicillin which feature a marked cellular accumulation (the amino function is situated in the sidechain of the drug). Moreover, we illustrate in the particular case of ampicillin a general procedure allowing one to modify, in a bioreversible way, the carboxylate function of a drug into a basic ester (an amino function being present in the alcoholic part of this ester). Finally, we stress that the four-membered ring of β -lactam antibiotics is weakened by esterification. Very labile esters could be promising prodrugs whereas

slowly hydrolysing esters give ring-opened derivatives in phosphate buffer at pH 7.4.

Results and Discussion


The context of the research: Design of esters of β -lactam antibiotics

Benzylpenicillin methyl ester has been the most studied compound. Early works (reviewed by Hamilton-Miller⁴) showed that it was inactive in vitro as well as in vivo, at least in man. The interest in penicillin esters thus faded until double esters (like pivampicillin **1**; Scheme 1) proved to be active in man. While benzylpenicillin methyl ester was not a substrate for esterases in larger mammals, its acetoxymethyl double ester was enzymatically hydrolysed and the generated benzylpenicillin hydroxymethyl ester spontaneously decomposed to benzylpenicillin and formaldehyde⁵ (Scheme 2).


It was discovered later on that human serum degraded benzylpenicillin methyl ester by opening of the β -lactam ring. Indeed, the ester was inactive not because its carboxylate function could not be regenerated, but because its β -lactam ring was cleaved first.⁶ Ring opening and ester cleavage are competitive reactions. The quickest process wins the race. Physico-chemical studies in buffers at

*Corresponding author. Fax: +32-2-764-7363; e-mail: sonveaux@cmfa.ucl.ac.be


physiological pH^{7–9} established the kinetic network presented in Scheme 3. The pH of 7.4 is situated in the base-catalysed domain of both ester hydrolysis and β -lactam ring opening.¹⁰ The productive pathway (k_p) liberates the active antibiotic while the non-productive pathway (k_{np}) yields inactive decomposition products. The generated β -lactam antibiotic itself eventually decomposes to ring-opened compounds (k_d). Page's team¹¹ found that,



Scheme 1. Discussed ampicillin basic prodrugs.



Scheme 2. Degradation path of acyloxymethyl esters of penicillins in human serum.



Scheme 3. Kinetic network describing the hydrolysis of penicillin esters at pH 7.4.

for benzylpenicillin methyl ester, the sum $k_p + k_{np}$ was sixteen times larger than k_d . The rate constant k_p being small in this case, this means that k_{np} equalled $16 k_d$. In other words, the β -lactam ring of the ester was sixteen times more labile than that of the parent drug. This proved to be true even when k_p was larger than k_{np} , i.e. in the case of efficient ester prodrugs. For example, pivampicillin and bacampicillin featured k_{np} s respectively twelve and 14 times larger than k_d .^{7,8}

Why is the β -lactam ring of penicillins weakened by esterification of the carboxylate function? The ester group is more electron-withdrawing than the carboxylate group, which increases both the electrophilicity of the β -lactam carbonyl carbon and the leaving-group ability of the β -lactam amino group.^{7,12} This electron-withdrawing effect is reflected in the shift of the amine pK_a from 5.2 for benzylpenicilloic acid to 3.2 for its methyl ester.¹¹

Useful esters of β -lactam antibiotics have thus to feature the following kinetic characteristics: $k_p > k_{np} = 12–16 k_d$. The k_p/k_{np} competition has to be pushed in the good direction by synthesising so called 'activated esters', i.e. labile esters. In the basic pH range, they have to be at least 20–30 times more labile than the β -lactam ring of the parent compound. However, a decent half-life of the ester prodrugs in the serum has to be maintained. These opposite requirements assign intrinsic limits to our approach.

Activated esters are usually obtained by enhancing the leaving group capability of the alcohol moiety by the mesomeric effect (e.g. *p*-nitrophenol) or the inductive effect (e.g. trifluoroethanol). Aromatic esters of β -lactam antibiotics being difficult to synthesise, we considered ampicillin esters of the type AMPI-COOCH₂X. There are severe limitations on X. It cannot be a carbonyloxy group (e.g. as in pivampicillin **1**), owing to the required resistance to human serum esterases. Compound **5** should be an exception (as stated before, the methyl ester of benzylpenicillin is not a good substrate for human esterases). The X function cannot be either an alkoxy R'O- or a carbonylamino R'CON(R'')- group because α -carboxymethyl ethers and α -carboxymethylamides spontaneously cleave by an S_N1 mechanism that does not require base catalysis, just like α -chloromethyl ethers. This uncatalysed process renders impossible the controlled release of ampicillin from a stable prodrug solution.^{13,14} To avoid a chloromethyl ether type of fission, the lone pair of X has to be strongly involved in mesomery. That is why we considered imide functions (X = N(COR)₂), i.e. compounds **2–4**. This type of ester was known to be much more rapidly hydrolysed than an ethyl ester at pH 7.4.¹⁵

Compounds **1–3** and **5** are basic owing to the amino function present in the phenylglycine sidechain of ampicillin. Compounds **4a,b** bear an additional amino function in the alcoholic part of the ester. Attachment of this alcoholic part to β -lactam antibiotics other than ampicillin would thus render them basic as well. Compounds **4a,b** were therefore synthesised to enlarge the


scope of the work. Moreover, if a monobasic molecule can theoretically be concentrated a hundred times in acidic organelles, dibasic ones could reach a theoretical maximum enrichment of ten thousand, based on the pH effect only.¹⁶ The structural characteristics we wanted for the basic alcoholic part of these esters were (i) the absence of chiral centre (to avoid epimerisation problems when working with chiral synthons or the obtention of a mixture of diastereoisomeric prodrugs when using racemic synthons), (ii) the lack of protection of the amino function (protections are difficult to remove in the presence of the β -lactam ring) and (iii) a good lipophilicity (to enhance the rate of cellular penetration). These requirements were met with **4a,b**.

Synthesis. The synthesis of **3** and **4a,b** are sketched in Scheme 4. A key reagent was the phosphorus ylid obtained by Michael addition of triphenyl (or tributyl) phosphine on maleimide.¹⁷ The double bond of **7a** and **7b**, obtained by the Wittig reaction, has the *E* configuration. Stabilised ylids usually indeed give the thermodynamically more stable olefin.^{18,19} The *Z* configuration of these succinimide derivatives would have a higher

energy content due to the steric clash between the imide carbonyl and the phenyl ring, impairing mesomery. By the way, the methylene of the imide ring of the *E* isomer sits in the deshielding area of the phenyl substituent, so that its chemical shift goes up by 0.3–0.4 ppm relative to the corresponding methylene of **10**, the synthon used to obtain **3**. Moreover, the olefinic hydrogen of **7a** or **7b** sits in the deshielding area of the carbonyl anisotropy double cone: the chemical shift of this hydrogen (7.53 ppm for **7a** and 7.64 for **7b**) fits well with the value calculated by additive rules (7.2 ppm for the *E* isomer versus 6.7 for the *Z* one²⁰).

The *N*-hydroxymethyl function of **8a,b**, obtained by condensation with formaldehyde, is incompatible with a free amino group, because it would promote the ionisation of the OH group and the expulsion of the imide anion.²¹ That is why the hydrobromide was engaged in the condensation with formaldehyde, instead of the free amine.

The bulky diisopropylamino function was used to prevent auto-alkylation of **9a**. We observed indeed that *N*-bromomethylphthalimide quantitatively alkylated triethylamine



Scheme 4. Synthesis of **4a**: [a] (1) Cs_2CO_3 , DMF; (2) $\text{Cl}-\text{CH}_2-\text{CH}_2-\text{N}[\text{CH}(\text{CH}_3)_2]_2$; [b] (1) HBr; (2) aqueous CH_2O ; [c] PBr_3 ; [d] see Scheme 5.

(DMF, room temperature, 24 h), while diisopropylethylamine did not react. We recognised afterwards, when synthesising **9b**, that the presence of two isopropyl groups on the amine function was not an absolute requirement, as long as the amine remained protected by protonation till the coupling with ampicillin. During the coupling itself, a competition was established between autoalkylation and alkylation of the carboxylate function of ampicillin but this latter reaction proved to be the fastest.

The reaction of *N*-bromomethylimides with ampicillin (on way to **2–4**) or of diiodomethane with ampicillin (on way to **5**) required the protection of the amino function of the phenylglycine sidechain. This was done by in situ condensation with benzaldehyde (Scheme 5). We verified that alkylation in these conditions took place on the carboxylate function of ampicillin (and not on its amino function) by *N*-acylating compound **2** with acetic anhydride in 90% yield. The acylated derivative featured two amide NH protons in ¹H NMR (the 6-CHNH and the 10-CHNH; see Scheme 1 for atom numbering).

A concern was also the possible epimerisation of the phenylglycine sidechain (at 10-C) due to the transient formation of its imine derivative by condensation with benzaldehyde, but both the ¹H and ¹³C spectra corresponded to a single diastereoisomer. Ampicillin epimers at 10-C are distinguishable even when using a 60 MHz instrument.²² In fact, aldehydes and ketones are known to react with ampicillin not to give an imine but an imidazolidinone ring,^{23,24} so that the α -hydrogen of the phenylglycine sidechain is not acidified, as should be the case if an imine was formed.

Hydrolysis of the esters. Imidomethyl esters of ampicillin are biologically active in cellular culture, as reported in our previous short communication.¹ This means that, at least in this medium, k_p was larger than k_{np} , or


of similar magnitude. The half-lives of compounds **1–5** ($=0.693/(k_p+k_{np})$), in phosphate buffer, pH 7.4, 37 °C, were determined by HPLC (Table 1). The hydrolysis was base-catalysed above pH 5.5 and followed first-order kinetics. The rate increased with the electron-withdrawing power of the alcoholic part of the ester (compare **2** with **3**), in agreement with the base-catalysed mechanism. The HPLC trace of the mixture obtained after pivampicillin **1** and prodrugs **2** and **3** stayed in the buffer during 1 half-life is shown in Figure 1(a). The correlation between the decrease in concentration of the prodrugs and the increase in concentration of released ampicillin is also shown (Fig. 1(b)). Ampicillin itself was only marginally degraded in these conditions ($t_{1/2}$ of ampicillin was 2144 min). The $k_p:k_{np}$ competition was in favour of ampicillin for quickly hydrolysing compounds **1**, **2**, **5** (ratios of ampicillin versus ring opened products of 66:34, 68:32 and 82:18, respectively). Less readily hydrolysing compounds, **3** and **4a**, generated a lower amount of ampicillin (ratios of 29:71 and 41:59, respectively: $k_{np} > k_p$). The addition of the released formaldehyde to ampicillin, giving an imidazolidinone ring,²⁵ was not an important side reaction in our conditions.

That β -lactam ring opening was a major degradation pathway was shown by LC–MS–MS (Tables 3–5).

Table 1. Half-lives (min) of compounds **1–5**

Compound	Half-life ^a (min)
Pivampicillin 1	92
2	62
3	191
4a	143
5	26

^aPhosphate buffer (0.02 M, NaCl 0.15 M, ethanol 1% v/v, pH 7.4, 37 °C).



Scheme 5. Synthesis of ampicillin esters **2–4**.

Samples of **1**, **2** and **3** were kept in an ethanol:water mixture (1:4, v/v) for 15 days at room temperature, and then analysed. The obtained compounds are sketched in Scheme 6. Besides the starting prodrugs and ampicillin, 5-*R*, 5-*S* ampicilloic acid esters **15** (pathway [b]) resulted from the decarboxylation of **13** (see refs 26 and 27 for mechanistic details). The ampicilloic acid disymmetric double esters **16**, resulting from the β -lactam ring opening by ethanol, and the piperazine-2,5-diones **14** were also found. The rearrangement of ampicilline itself in a piperazine-2,5-dione is a known reaction.²⁸





Figure 1. Hydrolysis of pivampicillin (**1**), **2** and **3** (1 mM) in phosphate buffer (0.02 M, NaCl 1.5 M, pH 7.4, 1% ethanol v/v) at 37 °C. (a) HPLC traces of the reaction mixtures after ca. a half-life of each compound (UV detection at 220 nm, uncorrected for differences on molar adsorptivity coefficients). a. is ampicillin; i.s. is the internal standard, benzamide; **13** (two epimers) and **14** are identified in Scheme 6. (b) Evolution of the relative molar concentrations (%) of the starting compound and of released ampicillin (a.) as a function of time.



Scheme 6. β -Lactam ring opening products identified by LC–MS–MS after prodrugs **1**, **2** or **3** (0.2 mg/mL) were kept 15 days at room temperature in an ethanol:water mixture (1:4). R has the same meaning as in Scheme 1.

resulting from the opening of the β -lactam ring by water and epimerisation via an intermediate imine (equilibrium [a]). 5-*R*, 5-*S* ampicilloic acid esters **15** (pathway [b]) resulted from the decarboxylation of **13** (see refs 26 and 27 for mechanistic details). The ampicilloic acid disymmetric double esters **16**, resulting from the β -lactam ring opening by ethanol, and the piperazine-2,5-diones **14** were also found. The rearrangement of ampicilline itself in a piperazine-2,5-dione is a known reaction.²⁸

The hydrolysis of active esters and the ring opening of β -lactams are subject to general acid–base and nucleophilic catalysis.¹⁰ Enzymes may also accelerate both reactions. To obtain a first information on the usefulness of our compounds in terms of effective release of the parent antibiotic, we measured their antibacterial potency in tryptic soy broth, in comparison with ampicillin. Table 2 gives their minimum inhibitory concentrations (MICs) against *S. aureus* in this culture medium. The determination entails a 24 h incubation at 37 °C, which should allow both productive (k_p) and non-productive disappearance of the prodrugs (k_{np}). The MICs of **2** and **5** were of the same order of magnitude as that of ampicillin, indicating that a large part of these prodrugs followed a productive degradation pathway. Conversely, slower hydrolysing esters **3** and **4a** displayed a lower activity than ampicillin, suggesting that, for these compounds, k_{np} indeed overwhelmed k_p . Results along the same line were obtained after ageing of the solutions. The MICs had a tendency to increase, probably due to the spontaneous degradation of the released ampicillin.

Perspectives


The method we used to synthesise basic and dibasic esters of ampicillin is general and could be applied to other penicillins and cephalosporins. The ester function of the most promising β -lactam prodrugs is more labile than their four-membered ring. Further work is in progress to fully characterise the cellular accumulation of these esters and to check their fate in human blood as well as their activity in vivo.

Table 2. Minimum inhibitory concentrations (MICs) of compounds 1–5

Compound	MIC ^a		MIC ^b	
	μ M	μ g/mL	μ M	μ g/mL
Ampicillin	0.3±0.1	0.1±0.05	0.5±0.1	0.2±0.05
Pivampicillin 1	0.5±0.1	0.25±0.05	0.6±0.1	0.3±0.05
2	0.4±0.1	0.2±0.05	0.5±0.1	0.3±0.05
3	1.2±0.3	0.7±0.2	1.2±0.3	0.7±0.2
4a	1.2±0.4	1±0.3	1.2±0.4	1±0.3
5	0.2±0.1	0.15±0.05	0.4±0.1	0.3±0.05

^aAgainst *Staphylococcus aureus* using freshly prepared solutions. The MIC is defined as the lowest concentration of antibiotic giving no visible bacterial growth (naked-eye examination) after 24 h incubation at 37 °C in tryptic soy broth 37 °C (initial pH 7.4), inoculum 10⁶ CFU/mL, dilutions tested: 0.05; 0.075; 0.1; 0.15; 0.2; 0.25; 0.3; 0.4; 0.5; 0.7; 1; 1.5 μ g/mL.

^bSame determination using an aged solution (24 h standing in tryptic soy broth (pH 7.4) at 37 °C).



Scheme 7. Principal fragments observed by LC–MS–MS.

Table 3. LC–MS–MS determination of the products of solvolysis of **1** (15 days, rt, ethanol:water mixture, 1:4 v/v)

Product	Retention time ^b	Epimer ^c	[M + H] ⁺	Main fragment ^d	
Ampicillin	5.6	—	350	[A + H] ⁺	160
13 ^a	13.4	14.2	482	[M + H - CO ₂] ⁺	438
14 ^a	17.1	—	464	[A + H] ⁺	274
1	21.3	—	464	[A + H] ⁺	274
15 ^a	21.7	23.0	438	[E] ⁺	278
16 ^a	27.0	—	510	[B + 2H] ⁺	237

^aSee Scheme 6, with R = R of **1** (see Scheme 1).

^bIn min. See Experimental.

^cRetention time of the epimer (see Scheme 6).

^dSee Scheme 7.

Table 4. LC–MS–MS determination of the products of solvolysis of **2** (15 days, rt, ethanol:water mixture, 1:4 v/v)

Product	Retention time ^c	Epimer ^d	[M + H] ⁺	Main fragment ^e	
Ampicillin	5.4	—	350	[A + H] ⁺	160
15 ^a	7.5	8.1	324	[M + H - NH ₃] ⁺	307
16 ^a	9.4	10.0	396	[B + 2H] ⁺	237
13 ^b	12.0	12.6	527	[M + H - CO ₂] ⁺	483
14 ^b	15.7	—	509	[A + H] ⁺	319
2	18.4	—	509	[A + H] ⁺	319
15 ^b	18.8	19.5	483	[D] ⁺	336
16 ^b	21.7	—	555	[A + H] ⁺	319

^aSee Scheme 6, with R = H.

^bSee Scheme 6, with R = R of **2** (see Scheme 1).

^cIn min. See Experimental.

^dRetention time of the epimer (see Scheme 6).

^eSee Scheme 7.

Table 5. LC–MS–MS determination of the products of solvolysis of **3** (15 days, rt, ethanol:water mixture, 1:4 v/v)

Product	Retention time ^b	Epimer ^c	[M + H] ⁺	Main fragment ^d	
Ampicillin	5.6	—	350	[A + H] ⁺	160
13 ^a	14.0	14.2	559	[M + H - CO ₂] ⁺	515
14 ^a	18.5	—	541	[A + H] ⁺	351
3	22.5	—	541	[A + H] ⁺	351
15 ^a	23.4–25	—	515	[D] ⁺	336
16 ^a	27.7	—	587	[A + H] ⁺	351

^aSee Scheme 6, with R = R of **3** (see Scheme 1).

^bIn min. See Experimental.

^cRetention time of the epimer (see Scheme 6).

^dSee Scheme 7.

Experimental

General

Solvents and reagents. Unless otherwise stated, commercially available solvents and reagents were used. 4-[3-(Dimethyl-amino)propoxy]benzaldehyde was from Aldrich Co.

IR spectroscopy. A Perkin–Elmer 457 spectrophotometer was used.

NMR spectroscopy. NMR spectra were recorded on a Bruker AC-300 instrument. Chemical shifts are reported in δ values (ppm) with TMS as an internal reference. Splitting patterns are indicated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet). For the ¹³C data, only selected signals are reported. The numbering of the carbons is indicated in Scheme 1.

HPLC analysis. Chromatographies were performed on a Gilson apparatus, injection loop of 100 μ L, using a precolumn filled with reversed phase C₁₈ powder and a reversed phase C₁₈ column (Adsorbosphere Alltech, 15 cm \times 4.6 mm) at a flow rate of 1 mL/min. Eluent A (acetonitrile:methanol:aqueous buffer, 10:10:80) was passed during 2 min, then a linear gradient of eluent B (same components, 50:20:30) in eluent A from 0 to 100%, over 5 min. The washing with 100% eluent B was maintained for 20 min. The aqueous buffer was an ammonium formate buffer, 0.02 M (adjusted at pH 5 with formic acid). The UV detection was performed at 220 nm. The ϵ_{220} s were determined: ampicillin, 6675; pivampicillin **1**, 6625; compound **2**, 43305; **3**, 12526; **4a**, 16802 l mol⁻¹ cm⁻¹. The hydrolysis of the samples (100 μ L) was stopped by addition of 7 μ L of HCl, 0.5 M (end pH = 5). The samples were placed in dry ice (for 3 h maximum) till the injection was performed.

LC–MS–MS analysis. These were run on a Thermo Separation Product AS-3000 chromatograph (column: Adsorbosphere Alltech, 25 cm \times 2.1 mm), coupled with a TSQ-7000 mass spectrometer working in the APCI mode (atmospheric pressure chemical ionisation). A linear gradient of eluent B in eluent A was used, from 0 to 100% over 10 min (flow rate 0.2 mL/min). The eluent and buffer were the same as above. We realised first an LC–MS experiment to set the parameters for the LC–MS–MS analysis, performed the same day.

Ampicillin phthalimidomethyl ester, hydrochloride (2). A mixture of ampicillin trihydrate (2 g, 5 mmol), potassium bicarbonate (0.5 g, 5 mmol), benzaldehyde (1 mL, 10 mmol) and DMF (50 mL) was stirred at 0 °C for 12 h to give an imidazolidinone (see Scheme 5), not isolated. Anhydrous magnesium sulfate (1.2 g, 10 mmol, heated at 800 °C for 24 h) was added to trap water, and, after a few min, a further equivalent of potassium bicarbonate (0.5 g, 5 mmol) and *N*-(bromomethyl)phthalimide (1.2 g, 5 mmol). After stirring 24 h at 0 °C, the mixture was poured into cold water (80 mL) and extracted with ethyl acetate (3 \times 60 mL). The organic extract was washed with brine (3 \times 50 mL), dried over magnesium sulfate and filtered. The filtrate, after evaporation under vacuum, was

stirred at -15°C for 20 min in a 1:1 mixture of acetonitrile and water (40 mL) adjusted at pH 2.5 with 0.5 M HCl. Water was added (40 mL) and the pH was adjusted to 5.0 by adding potassium bicarbonate. This solution was freed of acetonitrile by evaporation under vacuum, washed with ethyl acetate (4×50 mL) and saturated with sodium chloride. The formed precipitate was collected by filtration and washed with dichloromethane and ether. Yield 1.9 g, 76%, mp $159\text{--}160^{\circ}\text{C}$. Elemental analysis $\text{C}_{25}\text{H}_{25}\text{ClN}_4\text{O}_6\text{S}\cdot\text{H}_2\text{O}$: calcd C, 53.33, H, 4.83, N, 9.95, Na, 0.0; found C, 53.38, H, 4.94, N, 9.79, Na, 0.045. ^1H NMR (CD_3OD): $\delta = 1.39$ and 1.41 ($2 \times \text{s}$, 6H, $2 \times \text{CH}_3$), 4.40 (s, 1H, 3-CH), 5.07 (s, 1H, 10-CH), 5.46 and 5.57 ($2 \times \text{d}$, $J = 4.2$ Hz, 2H, 5- and 6-CH), 5.73 and 5.78 ($2 \times \text{d}$, $J = 10.6$ Hz, 2H, diastereotopic H's of O-CH₂-N), 7.47 (m, 5H, C₆H₅), 7.88 and 7.94 ($2 \times \text{m}$, 4 H, phthalimido group). ^{13}C NMR (CD_3OD): $\delta = 27.13$ and 31.21 ($2 \times \text{CH}_3$), 57.53 (6-C), 60.31 (10-C), 62.61 (2-C), 65.56 (5-C), 68.72 (3-C), 71.32 (O-CH₂-N), 167.92, 168.12, 168.85 and 173.62 (carbonyls). IR (KBr): 1790 cm^{-1} (ester C=O stretch.), 1775 (β -lactam C=O stretch.), 1750 , 1720 and 1705 (imide asym. and sym. C=O stretch. + sidechain amide C=O stretch.).

***N*-Acetylampicillin, phthalimidomethyl ester.** Triethylamine (0.4 mL, 2.8 mmol) and acetic anhydride (0.3 mL, 3 mmol) were added to a suspension of **2** (1 g, 2 mmol) in CH_2Cl_2 (20 mL) at $0\text{--}5^{\circ}\text{C}$. The reaction mixture was stirred at $0\text{--}5^{\circ}\text{C}$ for 4 h, washed with water, dried over magnesium sulfate and filtered. Ether was added to give a colourless solid. The solid was collected by filtration, washed with ether and dried over P_2O_5 in vacuo (yield, 0.9 g, 90%), mp $126\text{--}128^{\circ}\text{C}$. Elemental analysis $\text{C}_{27}\text{H}_{26}\text{N}_4\text{O}_7\text{S}\cdot 0.75\text{ H}_2\text{O}$: calcd C, 57.49, H, 4.91, N, 9.93; found C, 57.48, H, 4.84, N, 9.93. ^1H NMR (CDCl_3): $\delta = 2.01$ (s, 3H, CH_3CO), 5.55 (q, $J_1 = 4.2$ Hz, $J = 8.7$ Hz, 1H, 6-CH), 5.64 (d, $J = 6.9$ Hz, 1H, 10-CH), 6.85 (d, $J = 6.9$ Hz, 1H, 10-CHNH), 7.00 (d, $J = 8.7$ Hz, 1H, 6-CHNH). ^{13}C NMR (CDCl_3): $\delta = 23.08$ (CH_3CO), 166.36, 166.55, 169.77, 169.98 and 172.78 (carbonyls). IR (KBr): 1780 cm^{-1} (ester + β -lactam C=O stretch.), 1755 , 1730 and 1650 (imide + amides C=O stretch.).

Cyclohexylidenesuccinimide (10). Maleimide (1.0 g, 10 mmol) and tri-*n*-butylphosphine (2.1 mL, 10 mmol) in glacial acetic acid (15 mL) were heated at 80°C for 15 min and then left to stand for 1 h. The solvent was evaporated at 50°C (10 mm Hg) and the residue coevaporated with toluene (2×20 mL), leaving the ylid as a pink oily residue. Cyclohexanone (5 mL, 50 mmol) and K_2CO_3 (1.38 g, 10 mmol) were added. The mixture was heated at 100°C for 4 h and the excess of cyclohexanone was removed under vacuum (1 mm Hg) to give a red residue. This residue was partitioned between water and CH_2Cl_2 . The organic extract was dried (MgSO_4) and evaporated. The residue was crystallised in $\text{C}_2\text{H}_5\text{OH}$ (yield 0.34 g, 20%). Mp 166°C . ^1H NMR (CDCl_3): $\delta = 1.65$ (m, 6H), 2.16 (t, $J = 6$ Hz, 2H) and 2.98 (t, $J = 6.3$ Hz, 2H) (cyclohexylidene substituent), 3.25 (s, 2H, imide ring CH_2), 8.62 (1H, NH). ^{13}C NMR (CDCl_3): $\delta = 29.45$ (imide ring CH_2), 116.41 and 158.53 (olefinic Cs), 170.24 and 173.90 (imide carbonyls). IR (KBr): 3170 cm^{-1} , 3060 (NH stretch.), 1750, 1720 and 1710 (C=O stretch.), 1655 (C=C stretch.).

Exact mass: calcd for $\text{C}_{10}\text{H}_{13}\text{NO}_2$, 179.094629; found, 179.094564.

Cyclohexylidene-*N*-hydroxymethylsuccinimide (11). A mixture of cyclohexylidenesuccinimide (1 g, 6 mmol), 20% aqueous formaldehyde (10 mL, 66 mmol) and DMF (four drops) was heated at 100°C for 10 min with stirring, cooled and left to stand at room temperature. The white needles formed were collected, washed with water and dried over P_2O_5 (yield: 1.17 g, 100%). Mp $157\text{--}159^{\circ}\text{C}$. ^1H NMR (CDCl_3): $\delta = 3.69$ (t, $J = 7.8$ Hz, 1H, OH), 5.05 (d, $J = 7.8$ Hz, 2H, N-CH₂-O). ^{13}C NMR (CDCl_3): $\delta = 29.7$ (imide ring CH_2), 61.9 (N-CH₂-O). Exact mass: calcd for $\text{C}_{11}\text{H}_{15}\text{NO}_3$, 209.105194; found, 209.105114.

Cyclohexylidene-*N*-bromomethylsuccinimide (12). A suspension of the former compound (0.4 g, 2 mmol), phosphorus tribromide (0.52 g, 2 mmol) and toluene (2 mL) was refluxed for 4 h. The solution was left to settle and the supernatant was poured out. The insoluble residue was triturated with hot toluene (1–5 mL). The solid obtained after evaporation under vacuum of the combined toluene solutions was triturated with dry ether (3 mL). The solution was filtered and the filtrate evaporated in vacuo to leave a yellowish solid (yield 0.35 g, 70%). Mp 110°C . ^1H NMR (CDCl_3): $\delta = 5.28$ (s, 2H, N-CH₂-Br). ^{13}C NMR (CDCl_3): $\delta = 30.73$ and 31.74 (imide ring CH_2 and N-CH₂-Br). Exact mass: calcd for $\text{C}_{11}\text{H}_{14}\text{NO}_2\text{Br}$, 271.020790; found, 271.021280.

Ampicillin cyclohexylidenesuccinimidomethyl ester, hydrochloride (3). The same procedure was used as for compound **2**. The yield was 60%. Mp $176\text{--}177^{\circ}\text{C}$. Elemental analysis $\text{C}_{27}\text{H}_{33}\text{ClN}_4\text{O}_6\text{S}\cdot 1.5\text{ H}_2\text{O}$: calcd C, 53.68, H, 6.01, N, 9.27; found C, 53.46, H, 5.89, N, 9.25. ^1H NMR (CD_3OD): $\delta = 1.38$ and 1.41 ($2 \times \text{s}$, 6H, $2 \times \text{CH}_3$), 1.65 (m, 6H), 2.26 (m, 2H) and 3.03 (m, 2H) (cyclohexylidene substituent), 3.36 (s, 2H, imide ring CH_2), 4.38 (s, 1H, 3-CH), 5.13 (s, 1H, 10-CH), 5.46 (d, $J = 4.2$ Hz, 1H) and 5.57 (m, 3H) (5-CH, 6-CH and O-CH₂-N), 7.45–7.53 ($2 \times \text{m}$, 5H, C₆H₅). ^{13}C NMR (CD_3OD): $\delta = 26.99$ and 27.14 ($2 \times \text{CH}_3$), 57.50 (6-C), 60.03 (10-C), 62.86 (2-C), 65.57 (5-C), 68.69 (3-C), 71.31 (O-CH₂-N), 168.15, 168.92, 169.62, 173.64 and 174.78 (carbonyls). IR (KBr): $1800\text{--}1750\text{ cm}^{-1}$ (several unresolved bands) and 1700 (carbonyls C=O stretch.), 1655 (C=C stretch.).

4-(2-Diisopropylaminoethoxy)benzaldehyde (6a). 2-Diisopropylamino-ethyl chloride hydrochloride (3.2 g, 16 mmol) was partitioned between 5% Na_2CO_3 and CH_2Cl_2 . The organic phase was dried on MgSO_4 , filtered and evaporated, leaving the free amine (2.2 g, 84%). 4-Hydroxybenzaldehyde (1.65 g, 13.5 mmol) was dissolved in absolute methanol (120 mL, dried on Mg). Caesium carbonate (2.28 g, 7 mmol) was added. After stirring for 20 min at room temperature, the solvent was evaporated under vacuum (40°C , 3 h). The residue was dissolved in DMF (dried on CaH_2), and the mixture was evaporated again to remove all traces of methanol. A second volume of DMF was added (80 mL), followed by diisopropylaminoethyl chloride (2.2 g, 13.5 mmol). The mixture was heated at 65°C for 24 h, then filtered. The filtrate was concentrated and distilled to give a colourless

liquid (yield 2.4 g, 71%). Bp 137–138 °C/0.9 mm Hg. ¹H NMR (CDCl₃): δ = 0.96 (d, *J* = 6.5 Hz, 12 H, 4×CH₃), 2.76 (t, *J* = 7.3 Hz, 2H, CH₂-N), 2.96 (m, 2H, CH-N), 3.88 (t, *J* = 7.3 Hz, 2H, CH₂-O), 6.91 and 7.74 (2×d, *J* = 8.7 Hz, 4 H, C₆H₄), 9.79 (s, 1 H, CHO). ¹³C NMR (CDCl₃): δ = 190.58 (CHO). IR (film): 1690 cm⁻¹ (C=O stretch.). Exact mass: calcd for C₁₅H₂₃NO₂, 249.172879; found, 249.173264.

[4-(2-Diisopropylaminoethoxy)benzylidene]succinimide (7a). Maleimide (1.6 g, 16 mmol) and triphenylphosphine (4.2 g, 16 mmol) were stirred in glacial acetic acid (30 mL) at 70 °C for 0.5 h. Ether was added. The ylid precipitated as a white solid. It was dried in vacuo over P₂O₅ (yield: 5.1 g, 14 mmol, 89%). This ylid, DMSO (30 mL) and 4-(2-diisopropylamino-ethoxy)benzaldehyde (3.5 g, 14 mmol) were stirred at 80 °C for 3 h. A red coloration developed. DMSO was removed under reduced pressure at 60 °C, leaving a red glue. Trituration with dry ether gave a solid that was filtered and crystallised in CH₂Cl₂ (yield: 3.5 g, 76%). Mp 160–162 °C. ¹H NMR (CDCl₃): δ = 1.04 (d, *J* = 6.5 Hz, 12H, 4×CH₃), 2.82 (t, *J* = 7.3 Hz, 2H, CH₂-N), 3.04 (m, *J* = 6.5 Hz, 2 H, CH-N), 3.56 (d, *J* = 2.3 Hz, 2H, imide ring CH₂), 3.93 (t, *J* = 7.3 Hz, 2H, CH₂-O), 6.94 and 7.40 (2×d, *J* = 8.8 Hz, 4H, C₆H₄), 7.53 (t, *J* = 2.3 Hz, 1H, olefinic H). ¹³C NMR (CDCl₃): δ = 35.09 (imide ring CH₂), 121.06 and 134.87 (olefinic carbons), 171.26 and 174.23 (imide carbonyls). IR (KBr) 1755 and 1705 cm⁻¹ (C=O stretch.), 1645 (C=C stretch.). Exact mass: calcd for C₁₉H₂₆N₂O₃, 330.194343; found, 330.194602.

[4-(2-Diisopropylaminoethoxy)benzylidene]-N-hydroxymethylsuccinimide, hydrobromide (8a). The above described compound (2 g, 6 mmol) was dissolved by shaking 2 h at room temperature with one equivalent of HBr in water (70 mL). After filtration, water was evaporated under vacuum. The obtained white solid was washed with a large quantity of acetone (dried over K₂CO₃). It was dissolved in water (7 mL) at 80 °C. An equivalent of aqueous formaldehyde (0.486 g, 37%, 6 mmol) was added and the mixture was heated at 100 °C for 20 min. Evaporation under vacuum gave a white solid that was crystallised in ethanol. The crystals were filtered, washed with acetone and dried over P₂O₅ (yield: 1.3 g, 50%). Mp 207–208 °C. ¹H NMR ([D₆]DMSO): δ = 4.83 (2H, N-CH₂-O), 6.35 (1H, OH). ¹³C NMR ([D₆]DMSO): δ = 33.61 (imide ring CH₂), 60.52 (N-CH₂-O). Elemental analysis C₂₀H₂₉BrN₂O₄: calcd C, 54.42, H, 6.62, N, 6.35; found C, 54.35, H, 6.84, N, 6.37.

[4-(2-Diisopropylaminoethoxy)benzylidene]-N-bromomethylsuccinimide, hydrobromide (9a). A mixture of the above described compound (0.6 g, 1.36 mmol), ClCH₂-CHCl₂ (3.5 mL, dried over P₂O₅) and PBr₃ (1.2 mL, 12.7 mmol) was heated at 120 °C for 4 h. The hot mixture was filtered and evaporated under reduced pressure, leaving a yellow solid that was dried over P₂O₅. It was crystallised in CH₂Cl₂ (yield: 0.4 g, 59%). Mp 207–209 °C. ¹H NMR (CDCl₃): δ = 5.34 (s, 2H, N-CH₂-Br). ¹³C NMR (CDCl₃): δ = 30.89 and 34.07 (imide ring CH₂ and N-CH₂-Br).

Ampicillin, [4-(2-diisopropylaminoethoxy)benzylidene]succinimidomethyl ester, hydrochloride, (4a). Ampicillin trihydrate (0.24 g, 0.6 mmol) was alkylated as described for **2**, i.e. protected by benzaldehyde and esterified. The ester was extracted in ethyl acetate and then deprotected. When the aqueous deprotection mixture (freed from acetonitrile by partial evaporation) was saturated with sodium chloride, a yellow gum appeared. It was washed with dry ether and dried over P₂O₅ (0.3 g, 65%). The solid so formed was triturated with isopropanol (dried over MgSO₄) and the mixture was filtered on an HPLC filter (Millipore, HVHP, 0.45 μm) to remove sodium chloride. Isopropanol was partially evaporated under vacuum. A suspension was obtained, that was again filtered on an HPLC filter. This solution was evaporated, giving a solid that was dried over P₂O₅. Mp 170–172 °C. Elemental analysis C₃₆H₄₇Cl₂N₅O₇S·2.8 H₂O: calcd C, 53.04, H, 6.50, N, 8.59; found, C, 53.04, H, 6.38, N, 8.49. ¹H NMR (CD₃OD): δ = 1.61–1.66 (multiplet, 18 H, 6×CH₃), 3.88 (t, *J* = 4.7 Hz, 2H, OCH₂CH₂N), 3.92 (d, *J* = 1.8 Hz (allylic coupling), 2H, succinimide ring CH₂), 4.05 (m, *J* = 6.5 Hz, 2H, isopropyl CHs), 4.60 (s, 1H, 3-CH), 4.64 (t, *J* = 4.7 Hz, 2H, OCH₂CH₂N), 5.31 (s, 1H, 10-CH), 5.67 and 5.77 (2×d, *J* = 4.0 Hz, 2H, 5- and 6-CH), 5.86 (s, 2H, OCH₂N), 7.33 (d, *J* = 8.8 Hz, 2H) and 7.44–7.62 (8H, 3 multiplets) (C₆H₅, C₆H₄ and olefinic CH). ¹³C NMR (CD₃OD): δ = 17.38 and 19.09 (diastereotopic isopropyl CH₃s), 27.18 and 31.22 (2×CH₃ on the thiazolidine ring), 34.86 (imide ring CH₂), 57.53 (6-C), 60.34 (10-C), 63.09 (2-C), 65.61 (5-C), 68.74 (3-C), 71.36 (O-CH₂-N), 168.11, 168.91, 171.19, 173.63 and 174.83 (carbonyls). IR (KBr) 1775 cm⁻¹ and 1710 (C=O stretch.), 1640 (C=C stretch.).

[4-(3-Dimethylaminopropoxy)benzylidene]succinimide (7b). The same procedure was used as for the diisopropyl analogue, except that CHCl₃ was used as a solvent for the Wittig reaction instead of DMSO. Yield: 73%. Mp 187.0–189 °C. ¹H NMR (CDCl₃ and CF₃COOH): δ = 2.30 (m, 2H, NCH₂CH₂CH₂O), 3.03 (d, *J* = 5.0 Hz, 6H, 2×CH₃), 3.45 (m, 2H, CH₂-N), 3.68 (s, 2H, imide ring CH₂), 4.16 (t, 2H, CH₂-O), 6.91 and 7.43 (2×d, *J* = 8.5 Hz, 4H, C₆H₄), 7.64 (s, 1H, olefinic CH). ¹³C NMR (CDCl₃ and CF₃COOH): δ = 34.79 (imide ring CH₂), 120.47 and 136.67 (olefinic carbons), 173.11 and 176.04 (imide carbonyls). IR (KBr): 1740 cm⁻¹ and 1700 (C=O stretch.), 1650 (C=C stretch.). Exact mass: calcd for C₁₆H₂₀N₂O₃, 288.147393; found, 288.146918.

[4-(3-Dimethylaminopropoxy)benzylidene]-N-hydroxymethylsuccinimide, hydrobromide (8b). The HBr salt of the former compound was obtained by dissolution in trifluoroacetic acid, treatment with one equivalent of concentrated aqueous HBr and evaporation. The residual solid was washed with ether. The same reaction procedure was then used as for the diisopropyl analogue. Yield 59%. Mp 198 °C. ¹H NMR ([D₆]DMSO): δ = 4.86 (d, *J* = 6.5 Hz, 2H, N-CH₂-O), 6.38 (t, *J* = 6.5 Hz, 1H, OH). ¹³C NMR ([D₆]DMSO): δ = 33.86 (imide ring CH₂), 60.73 (N-CH₂-O). Elemental analysis C₁₇H₂₃BrN₂O₄: calcd C, 51.14, H, 5.81, N, 7.02; found C, 51.04, H, 5.97, N, 7.09.

[4-(3-Dimethylaminopropoxy)benzylidene]-N-bromomethylsuccinimide, hydrobromide (9b). The procedure was the same as for the diisopropyl analogue, except that acetonitrile (dried over P_2O_5) was used as a solvent instead of trichloroethane. Yield 69%. Mp 224–225 °C. 1H NMR ($CDCl_3$): δ = 5.35 (s, 2H, N- CH_2 -Br). ^{13}C NMR ($CDCl_3$): δ = 30.90 and 34.12 (N- CH_2 -Br and imide ring CH_2).

Ampicillin [4 - (3 - dimethylaminopropoxy)benzylidene]succinimidomethyl ester, hydrochloride (4b). Ampicillin trihydrate (0.27 g, 0.67 mmol) was alkylated as described for **4a** and the product was isolated in the same way. Yield 62%. Mp 188–190 °C. Elemental analysis $C_{33}H_{41}Cl_2N_5O_7S \cdot 2H_2O$: calcd C, 52.24, H, 5.98, N, 9.23; found C, 52.15, H, 5.89, N, 8.85. 1H NMR (CD_3OD): δ = 1.14 and 1.17 (2×s, 2×3 H, 2× CH_3), 2.28 (m, 2H, $OCH_2CH_2CH_2N$), 2.95 (s, 6H, N(CH_3) $_2$), 3.38 (t, J = 7.9 Hz, 2H, $OCH_2CH_2CH_2N$), 3.69 (s, 2H, succinimide ring CH_2), 4.19 (t, J = 5.6 Hz, 2H, $OCH_2CH_2CH_2N$), 4.39 (s, 1H, 3-CH), 5.11 (s, 1H, 10-CH), 5.45 and 5.56 (2×d, J = 3.9 Hz, 2×1H, 5- and 6-CH), 5.64 (s, 2H, O- CH_2 -N), 7.07 (d, J = 8.6 Hz, 2H) and 7.45–7.58 (m, 8H) (C_6H_5 , C_6H_4 and olefinic CH). ^{13}C NMR (CD_3OD): δ = 25.67 ($OCH_2CH_2CH_2N$), 27.17 and 31.22 (2× CH_3), 34.86 (imide ring CH_2), 43.66 (N(CH_3) $_2$), 56.57 ($OCH_2CH_2CH_2N$), 57.52 (6-C), 60.33 (10-C), 63.08 (2-C), 65.59 (5-C), 66.26 ($OCH_2CH_2CH_2N$), 68.72 (3-C), 71.35 (O- CH_2 -N), 168.11, 168.89, 171.22, 173.61 and 174.87 (carbonyls). IR (KBr) 1770 cm^{-1} and 1710 (C=O stretch.), 1635 (C=C stretch.).

Diampicillylmethane, dihydrochloride (5). Potassium bicarbonate (0.496 g, 4.96 mmol) and benzaldehyde (1 mL, 9.92 mmol) were added to a suspension of ampicillin trihydrate (2 g, 4.96 mmol) in DMF (20 mL). The mixture was stirred at 0–4 °C for 12 h. Anhydrous magnesium sulfate (2.4 g, 19.9 mmol) was added and the mixture was further stirred for 2–3 h. The reaction mixture was left at 4 °C for 9 days, after the addition of CH_2I_2 (4 mL, 49.6 mmol) and of a further amount of potassium bicarbonate (0.496 g, 4.96 mmol). Evaporation of the mixture after filtration gave a yellow solid that was washed with ether, dried over P_2O_5 , dissolved in ethyl acetate and submitted to flash-chromatography (100 g of silica, eluent: ethyl acetate, R_f = 0.85). The obtained bis-pyrazolidinone was deprotected at pH 2.5 as described for **2**. The precipitation with sodium chloride gave a gum. After the brine was poured out, the gum was washed with ether and dried in vacuo over P_2O_5 . The resulting powder was purified by dissolution in isopropanol as described for **4a**. Yield: 36%. Mp 190–191 °C. Elemental analysis $C_{33}H_{40}Cl_2N_6O_8S_2 \cdot 1.5H_2O$: calcd C, 48.89, H, 5.35, N, 10.36; found C, 49.00, H, 5.36, N, 10.09. 1H NMR (CD_3OD): δ = 1.39 and 1.45 (2×s, 12 H, 4× CH_3), 4.41 (s, 2 H, 3-CH), 5.08 (s, 2 H, 10-CH), 5.46 and 5.57 (2×d, J = 4.0 Hz, 2×2H, 5- and 6-CH), 5.86 (s, 2 H, O- CH_2 -O), 7.47 (m, 10 H, C_6H_5). ^{13}C NMR (CD_3OD): δ = 27.18 and 31.10 (4× CH_3), 57.53 (6-C), 60.32 (10-C), 65.47 (5-C), 68.71 and 71.31 (2-C and 3-C), 81.61 (O- CH_2 -O), 129.47, 130.39, 131.14, 133.93 (C_6H_5), 167.80, 168.94 and 173.60 (carbonyls). IR (KBr): 1770 cm^{-1} (ester and β -lactam C=O stretch.), 1685 (amide C=O stretch.).

Acknowledgements

I. Paternotte had a fellowship of the Belgian Fonds pour la Formation à la Recherche dans l'Industrie et dans l'Agriculture. This work was supported by the Belgian Fonds National de la Recherche Scientifique (grant no. 1.5113.00), the Belgian Fonds de la Recherche Scientifique Médicale (grant no. 3.4516.94) and the Fonds Spécial de Recherche from the Université Catholique de Louvain. We thank Professor E. De Hoffmann for his help in mass spectroscopy. We also thank the Leo Pharmaceutical Products Co., Denmark, for the gracious gift of pivampicillin.

References and Notes

- Fan, H. J.; Paternotte, I.; Vermander, M.; Li, K.; Beaujean, M.; Scorneaux, B.; Dumont, P.; Osinski, P.; Claesen, M.; Tulkens, P. M.; Sonveaux, E. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 3107.
- van den Broek, P. J. *Rev. Infect. Dis.* **1989**, *11*, 213.
- Tulkens, P. M. *Eur. J. Clin. Microbiol. Infect. Dis.* **1991**, *10*, 100.
- Hamilton-Miller, J. M. T. *Chemotherapy* **1967**, *12*, 73.
- Agersborg, H. P. K.; Batchelor, A.; Cambridge, G. W.; Rule, A. W. *Brit. J. Pharmacol.* **1966**, *26*, 649.
- Nielsen, N. M.; Bundgaard, H. *J. Pharm. Pharmacol.* **1988**, *40*, 506.
- Toney-Parker, T. E.; Notari, R. E. *Drug Stab.* **1995**, *1*, 40.
- Fujiwara, H.; Kawashima, S. *Chem. Pharm. Bull.* **1985**, *33*, 1202.
- Nguyen, N.-A. T.; Mortada, L. M.; Notari, R. E. *Pharm. Res.* **1988**, *5*, 288.
- Connors, K. A.; Amidon, G. L.; Stella, V. J. In *Chemical Stability of Pharmaceuticals, a Handbook for Pharmacists*; J. Wiley & Sons: New York, 1986; pp 198–207, 274–283.
- Proctor, P.; Gensmantel, N. P.; Page, M. I. *J. Chem. Soc., Perkin Trans. II* **1982**, 1185.
- Laws, A. P.; Layland, N. J.; Proctor, D. G.; Page, M. I. *J. Chem. Soc., Perkin Trans. II* **1993**, 17.
- Vanwetswinkel, S.; Carlier, V.; Marchand-Brynaert, J.; Fastrez, J. *Tetrahedron Lett.* **1996**, *37*, 2761.
- Moreira, R.; Calheiros, T.; Cabrita, J.; Mendes, E.; Pimentel, M.; Iley, J. *Pharm. Res.* **1996**, *13*, 70.
- Saari, W. S.; Freedman, M. B.; Hartman, R. D.; King, S. W.; Raab, A. W.; Randall, W. C.; Engelhardt, E. L.; Hirschmann, R.; Rosegay, A.; Ludden, C. T.; Scriabine, A. *J. Med. Chem.* **1978**, *21*, 746.
- de Duve, C. T.; de Barsey, T.; Poole, B.; Trouet, A.; Tulkens, P.; Van Hoof, F. *Biochem. Pharmacol.* **1974**, *23*, 249524.
- Hedaya, E.; Theodoropoulos, S. *Tetrahedron* **1968**, *24*, 2241.
- Carey, F. A.; Sundberg, R. J. In *Advanced Organic Chemistry*; Plenum Press: New York, 1983; Vol. B, pp 71–73.
- March, J. In *Advanced Organic Chemistry, Reactions, Mechanisms and Structure*; J. Wiley & Sons: New York, 1992; p 960.
- Silverstein, R. M.; Clayton Bassler, G.; Morrill, T. C. In *Spectrometric Identification of Organic Compounds*; J. Wiley & Sons: New York, 1991; p 215.
- Johansen, M.; Bundgaard, H. *Arch. Pharm. Chem. Sci. Ed.* **1979**, *7*, 175.
- Bird, A. E.; Steele, B. R.; Boles, M. O.; Gane, P. A. C. *J. Chem. Soc., Perkin Trans. I* **1982**, 563.

23. Hardcastle Jr., G. A.; Johnson, D. A.; Panetta, C. A. *J. Org. Chem.* 1966, 897.
24. Klixbüll, U.; Bundgaard, H. *Int. J. Pharmaceutics* **1985**, 23, 163.
25. Bundgaard, H.; Klixbüll, U. *Int. J. Pharmaceutics* **1985**, 27, 175.
26. Bird, A. E.; Cutmore, E. A.; Jennings, K. R.; Marshall, A. C. *J. Pharm. Pharmacol.* **1983**, 35, 138.
27. Robinson-Fuentes, V. A.; Jefferies, T. M.; Branch, S. K. *J. Pharm. Pharmacol.* **1997**, 49, 843.
28. Bundgaard, H.; Hansen, J. *Int. J. Pharmaceutics* **1981**, 9, 273.